Mosquito-borne disease is reemerging in the United States as warming temperatures and insecticide resistance let Aedes and other vectors return; 2024 saw nearly 4,000 dengue cases (a 360 percent jump from the prior-decade average), locally transmitted infections in Florida, California, and Texas, Puerto Rico’s dengue emergency, and malaria’s first U.S. cluster in two decades. Powerful suppression tools already exist: Oxitec’s engineered males carry a lethal tTAV gene that kills female offspring and drove Aedes populations down by ~80 percent in the Cayman Islands and ~95 percent in Juazeiro, Brazil, while decades‑old sterile‑insect methods have eradicated pests like screwworm and controlled Mediterranean fruit fly. Oxitec’s technology has been stalled by jurisdictional shuffling (USDA → FDA → EPA), long reviews, an Experimental Use Permit in 2020, paused field releases after public pushback, and a commercial registration still pending after its permit expired in 2024.
An alternative, Wolbachia-based approaches either seed mosquito populations with a virus-blocking bacterium or release infected males to induce sterility; randomized trials in Singapore showed ~85 percent mosquito reduction and ~70 percent fewer dengue cases. MosquitoMate won full nationwide EPA registration for a live mosquito biopesticide in April 2024, with deployments in the Florida Keys (2025) and San Gabriel Valley (2026), and larger projects (e.g., Google’s Debug) seeking permits for Culex control. The central contention is that regulatory frameworks have not kept pace with biotech advances, and faster, clearer approval paths would let the United States use proven, low‑environmental‑cost tools to eliminate domestic mosquito-borne disease.
Summary generated by AI from the linked article. hn.today is not affiliated with Hacker News or Y Combinator.